Obalon Therptcs (NASDAQ: OBLN) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare Obalon Therptcs to related businesses based on the strength of its profitability, risk, earnings, valuation, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Obalon Therptcs and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Obalon Therptcs -459.54% -59.77% -47.02%
Obalon Therptcs Competitors -101.23% -91.82% -29.87%

Insider & Institutional Ownership

43.8% of Obalon Therptcs shares are owned by institutional investors. Comparatively, 57.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 16.4% of Obalon Therptcs shares are owned by insiders. Comparatively, 11.2% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Obalon Therptcs and its peers revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Obalon Therptcs $3.39 million -$20.46 million -4.04
Obalon Therptcs Competitors $1.67 billion $207.58 million 78.09

Obalon Therptcs’ peers have higher revenue and earnings than Obalon Therptcs. Obalon Therptcs is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Obalon Therptcs and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Obalon Therptcs 1 0 2 0 2.33
Obalon Therptcs Competitors 109 727 1024 10 2.50

Obalon Therptcs currently has a consensus target price of $12.00, suggesting a potential upside of 49.44%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.11%. Given Obalon Therptcs’ higher probable upside, equities research analysts plainly believe Obalon Therptcs is more favorable than its peers.

Summary

Obalon Therptcs peers beat Obalon Therptcs on 7 of the 11 factors compared.

Obalon Therptcs Company Profile

Obalon Therapeutics, Inc. is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.

Receive News & Ratings for Obalon Therptcs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obalon Therptcs and related companies with MarketBeat.com's FREE daily email newsletter.